Skip to content

effects of curcumine in stroke

Evaluation of the effect of Nano Micelle curcumin of patient with ischemic stroke: triple-blind placebo-controlled randomized clinical trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180803040679N1
Enrollment
80
Registered
2019-01-03
Start date
2019-01-04
Completion date
Unknown
Last updated
2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute ischemic stroke. Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries

Interventions

Intervention 1: Intervention group: The intervention group will receive 80mg of Curcumin pearl everyday for 8 weeks accompanied with acute ischemic stroke treatments. The first dose will be administer

Sponsors

Mashhad University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age between 50-80 years First ever stroke patients Ischemic stroke GCS<13 NIHSS=4-25 MRS<2 before the stroke Stroke occurrence within prior 12 hours.

Exclusion criteria

Exclusion criteria: Fever at first presentation Presence of other inflammatory conditions Immunosuppressive drug consumption Death within the first week of the study Presence of bedsore during follow-up Occurrence of myocardial infarction during the study follow-up Pregnancy TIA 3 month prior to study Massive brain infarction Declining to participate History of allergy to Turmeric Advanced hepatic conditions malabsorption syndrome History of diabetes Receiving rTPA Mechanical thrombectomy during the study follow-up Presence of dementia Craniotomy during the study follow-up BMI more than 35 Cigarette smoking Alcohol consumption

Design outcomes

Primary

MeasureTime frame
Stroke severity. Timepoint: before intervention, 4 days, 8 weeks and 3 month after intervention. Method of measurement: using NIHSS.;Degree of disability/dependence. Timepoint: before intervention, 4 days, 8 weeks and 3 month after intervention. Method of measurement: using MRS.

Secondary

MeasureTime frame
Activities of Daily Living. Timepoint: before intervention, 4 days, 8 weeks and 3 month after intervention. Method of measurement: Barthel index.;Seizure. Timepoint: before intervention, 4 days, 8 weeks and 3 month after intervention. Method of measurement: according to clinical presentations.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFariborz Rezaeitalab

Mashhad University of Medical Sciences

rezaeitalabf@mums.ac.ir+98 51 3760 5917

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026